CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
CVM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading CVM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.66%68.831.0%$926.55m
AMGNAmgen Inc.
-0.31%172.610.8%$655.47m
BIIBBiogen Inc.
0.25%287.630.9%$526.94m
CELGCelgene Corporation
-0.14%119.271.0%$480.99m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%370.221.9%$341.26m
ALXNAlexion Pharmaceuticals, Inc.
0.72%130.832.0%$299.85m
TSROTESARO, Inc.
-0.17%189.9415.3%$195.91m
INCYIncyte Corporation
-0.82%121.362.3%$163.54m
ILMNIllumina, Inc.
0.09%162.303.9%$144.45m
VRTXVertex Pharmaceuticals Incorporated
-0.88%85.792.6%$139.38m
EXELExelixis, Inc.
-2.12%22.625.5%$127.92m
CLVSClovis Oncology, Inc.
-2.86%61.1916.4%$127.65m
AAgilent Technologies, Inc.
-0.04%51.331.7%$116.31m
ACADACADIA Pharmaceuticals Inc.
-0.15%39.1419.0%$93.49m
BMRNBioMarin Pharmaceutical Inc.
-0.50%89.794.0%$90.43m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.